Replies to post #396879 on Amarin Corp Plc (AMRN)

[JRoon71]

BBI, normally I would agree (with a typical "new drug"). However, I think in this case, the generics might have seen the writing on the wall that Omega-3's are becoming wildly popular right now, and they wanted to hitch their wagon to that horse. All Omega-3's are enjoying a nice run right now with virtually zero out-of-pocket marketing...Lovaza, Vascepa, generics, and OTC fish oil.

In hindsight, you are right. If Amarin had never lost the patents, and had free run of marketing the past 3 years, I would suspect their run rate would be probably double what it is now. Maybe more. Just over two years ago we were at 100,000 scripts a week and growing (we doubled scripts in about 18 months), and we had just expanded the salesforce and were barely marketing.

What we also can't account for is the fact that all of the additional cashflow would have moved up all plans for marketing and rollouts of new formulations.

Losing the patent protection had such a profound and magnified impact on Amarin. More than I think many people even realize. Everything since then has simply been defensive/scramble mode.

[rosemountbomber]

That is one of the most puzzling aspects of the Amarin saga. Surprising too because the Generics are not amateurs but experienced at what they do. They could have waited a few more years and reaped far greater rewards.

[retinadoc]

That business reality is exactly why a real CEO and BOD would have come to a mutually beneficial agreement after the Du debacle. That can still happen, but it will require Sarissa to gut Amarin's pathetic management and think outside the box.

Denner's team can do so or find a pharma that is willing.

[ralphey]

MOSt likely generics thought as I did .

#1 killer above 40 worldwide
FIrst new proven intervention beyond statins
almost no side effects

BLOCKBUSTER !!! It will take off by itself !

Indeed a fascinating study on how practitioners obtain unbiased information on how to practice their art. This should actually be rather alarming to those of us who believe in the free exchange of information to seek truth

[Meowza]

No. It was never just 40 percent of one market, for just one drug. That utterly fails to capture the full scope of Hikma's upside in achieving patent invalidation:

https://www.globenewswire.com/en/news-release/2022/12/08/2570183/0/en/Corcept-Therapeutics-Settles-Patent-Litigation-with-Hikma-Pharmaceuticals.html

http://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-reaches-settlement-hikma-pharmaceuticals

https://www.robinskaplan.com/results/2022/06/reached-settlement-for-hikma-pharmaceuticals-in-hatch-waxman-litigation